50 Million
Approximately 50 million adults in the U.S. experienced a mental illness in 2019
Mental Health AmericaRelmada Therapeutics, Inc.
Taking on major depressive disorder
Major depressive disorder (MDD) is a serious mental health condition that affects over 300 million people globally, making it a leading cause of poor health and disability on the planet. MDD is expressed through a loss of interest and pleasure in life and impairs motivation and cognitive abilities, undermining how people function at work, school, and in social circles.
New options for MDD
Our team is focused on improving treatment options without sacrificing the quality of life for those living with MDD.
The impact of MDD, and what is considered to be successful treatment, can vary from person to person. We feel there is a need to provide options that:
- Provide rapid relief
- Attain high remission rates
- Improve cognitive functioning
- Are safe and well tolerated
- Potentially modify the course of CNS disorders
Neural plasticity: rewiring connections
In a healthy functioning brain, neurons respond to external experiences by modifying existing connections or creating new ones.
There is increasing evidence that depression is caused by impaired neural plasticity in specific circuits and regions of the brain associated with mood and cognition.
Our goal is to leverage our understanding of neural plasticity to develop new treatment options for CNS disorders, including MDD. Using this rationale, we hypothesize that REL-1017 preferentially blocks hyperactive NMDAR channels that are associated with MDD. REL-1017 has the potential to provide patients with rapid relief by restoring physiological neural plasticity, which would improve symptoms and be potentially curative.
